Skip to main content
. 2021 Oct 15;24(5):809–820. doi: 10.1093/neuonc/noab239

Fig. 2.

Fig. 2

PFS and OS according to pTERT mutation (A, B) and EGFR amplification (C, D). Comparison between combined pTERT and EGFR-intact subgroup and either pTERT-mutant or EGFR-amplified subgroup for PFS (E) and OS (F).